Breaking barriers: Smart vaccine platforms for cancer immunomodulation

Abstract Despite significant advancements in cancer treatment, current therapies often fail to completely eradicate malignant cells. This shortfall underscores the urgent need to explore alternative approaches such as cancer vaccines. Leveraging the immune system's natural ability to target and...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohammad Mahmoudi Gomari, Taha Ghantabpour, Nima Pourgholam, Neda Rostami, Stephen M. Hatfield, Farzaneh Namazifar, Shadi Abkhiz, Seyed Sadegh Eslami, Mahsa Ramezanpour, Mahsa Darestanifarahani, Igor Astsaturov, Sidi A. Bencherif 
Format: Article
Language:English
Published: Wiley 2025-05-01
Series:Cancer Communications
Subjects:
Online Access:https://doi.org/10.1002/cac2.70002
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Despite significant advancements in cancer treatment, current therapies often fail to completely eradicate malignant cells. This shortfall underscores the urgent need to explore alternative approaches such as cancer vaccines. Leveraging the immune system's natural ability to target and kill cancer cells holds great therapeutic potential. However, the development of cancer vaccines is hindered by several challenges, including low stability, inadequate immune response activation, and the immunosuppressive tumor microenvironment, which limit their efficacy. Recent progress in various fields, such as click chemistry, nanotechnology, exosome engineering, and neoantigen design, offer innovative solutions to these challenges. These achievements have led to the emergence of smart vaccine platforms (SVPs), which integrate protective carriers for messenger ribonucleic acid (mRNA) with functionalization strategies to optimize targeted delivery. Click chemistry further enhances SVP performance by improving the encapsulation of mRNA antigens and facilitating their precise delivery to target cells. This review highlights the latest developments in SVP technologies for cancer therapy, exploring both their opportunities and challenges in advancing these transformative approaches.
ISSN:2523-3548